MYRIAD GENETICS, INC. Non Peo Neo Avg Total Comp Amt
MYRIAD GENETICS, INC. (MYGN) reported Non Peo Neo Avg Total Comp Amt of $2.86 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-14.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-14
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $2.86M DEF 14A · filed 2026-04-14 |
| 2024-12-31 | $3.48M DEF 14A · filed 2026-04-14 |
| 2023-12-31 | $4.14M DEF 14A · filed 2026-04-14 |
| 2022-12-31 | $2.67M DEF 14A · filed 2026-04-14 |
| 2021-12-31 | $2.48M DEF 14A · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |